Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 13 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The revenue forecast reflects the positive impact of foreign exchange movements. The increase in revenue is expected to be the main driver of operating profit, although this will be partly offset by higher operating expenses due to foreign exchange movements and accelerated investment ahead of the launch of new products, mainly zasocitinib. Net income is expected to benefit from lower income tax expense following a reassessment of the recoverability of deferred tax assets, although this will be partly offset by financial losses.
¥100 billion in impairment losses on product-related intangible assets (a key assumption underlying the full-year earnings forecast). Impairment losses for the interim period were ¥30,855 million.
| Item | Details |
|---|---|
| Net Sales | ¥46,400 100 million → ¥47,000 100 million（+1.3%） |
| Operating profit | ¥4,200 100 million → ¥4,530 100 million（+7.9%） |
| Profit attributable to owners of the parent | ¥1,660 100 million → ¥2,090 100 million（+25.9%） |
| Net income per share | 104.26 yen → 131.28 yen（+25.9%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 May 2026 |
| Reason for the revision | The revenue forecast reflects the positive impact of foreign exchange movements. The increase in revenue is expected to be the main driver of operating profit, although this will be partly offset by higher operating expenses due to foreign exchange movements and accelerated investment ahead of the launch of new products, mainly zasocitinib. Net income is expected to benefit from lower income tax expense following a reassessment of the recoverability of deferred tax assets, although this will be partly offset by financial losses. |
| Details and amount of extraordinary loss | ¥100 billion in impairment losses on product-related intangible assets (a key assumption underlying the full-year earnings forecast). Impairment losses for the interim period were ¥30,855 million. |
| Dividend forecast revision | No change (annual dividend forecast: ¥204 per share) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The revenue forecast reflects the positive impact of foreign exchange movements. The increase in revenue is expected to be the main driver of operating profit, although this will be partly offset by higher operating expenses due to foreign exchange movements and accelerated investment ahead of the launch of zasocitinib. Net income is expected to benefit from lower income tax expense following a reassessment of the recoverability of deferred tax assets, partly offset by financial losses.